

## **Eligibility and Payments Policy Branch**

# SOP Bulletin No. 212

13 January 2020

#### THE FOLLOWING RMA SOPS TAKE EFFECT ON 27 JANUARY, 2020

New SOPs	Nil
Revocations & Replacements	Kaposi sarcoma
Amendments	Nil

#### **NOTEWORTHY FEATURES**

Kaposi sarcoma	Revocation – 1 & 2 of 2020
	Replaces 9 & 10 of 2011

- There has been a name change, from "Kaposi's sarcoma", in keeping with the RMA's policy for eponymously named diseases.
- The definition has been amended but SOP coverage is unchanged.
- The immunosuppressive drugs factor now covers a broader range of agents.
- There are new RH and BOP factors for: non-Hodgkin lymphoma; chronic lymphocytic leukaemia/small lymphocytic lymphoma; and, treatment with angiotensin converting enzyme inhibitors.

• There are new RH only factors for: chronic renal failure; autoimmune diseases; lymphoedema; and diabetes.

### **Contact for this bulletin:**

Dr Jon Kelley

X470412